Company Profile

tella, Inc. is a Japan-based company mainly engaged in the provision of techniques and operational knowhow associated with cell medicines, as well as the research and development of regenerative medicine and cell medicine. The Company operates through three business segments. The Cell Medicine segment is engaged in the provision of cancer treatment technology and operational method centered on dendritic cell vaccine therapy. This segment is also engaged in the provision of Services for contract medical institutions, such as cell culture system maintenance support services, management system maintenance support services and disease support services. The Medical Support segment is mainly engaged in the provision of drug development services (CROs) and genetic testing services. The Pharmaceutical segment is engaged in the development of the dendritic cell vaccine for regulatory approval as a product for cancer regenerative medicine.

Employees

Sector

Biotechnology & Medical Research

More about the company

20/09/21	Tella, Inc.(JASDAQ:2191) dropped from S&P Global BMI Index	CI
28/05/21	Beroni Group Signs Mou with tella, Inc. to Collaborate in Immunotherapy for Cancer Treatment	CI
09/03/21	Argentina Tries to Tax and Spend Its Way Out of an Economic Crisis	DJ
28/12/20	Cenegenics Japan Co., Ltd. completed the acquisition of 51% stake in Prometheus. Biotech Corporation. from tella, Inc..	CI
25/12/20	Cenegenics Japan Co., Ltd. agreed to acquire 51% stake in Prometheus. Biotech Corporation. from tella, Inc. for ¥153 million.	CI
16/12/20	Tella, Inc. announced that it has received ¥1.0010013 billion in funding from Cenegenics Japan Co., Ltd.	CI
28/10/20	Tella, Inc. announced that it expects to receive ¥1.0010013 billion in funding from Cenegenics Japan Co., Ltd.	CI
21/09/20	Tella, Inc.(JASDAQ:2191) added to S&P Global BMI Index	CI
01/09/20	Argentina defuses default crisis with 'massive' debt deal	RE
26/08/20	Tella, Inc. acquired 51% stake in Prometheus Biotech Corporation from Cenegenics Japan Co., Ltd. for approximately ¥150 million.	CI
15/08/20	Shogo Kozuka cancelled the acquisition of TITAN Inc. from tella, Inc. from tella, Inc..	CI
05/08/20	Now for the hard part: Argentina must fix economy after debt deal	RE
15/08/19	Shogo Kozuka agreed to acquire TITAN Inc. from tella, Inc. from tella, Inc..	CI

Manager	Title	Age	Since
Kiyoto Kiuchi PSD	President	35	29/03/2022
Toshinobu Ihara ADM	Chief Administrative Officer	-	-

Director	Title	Age	Since
Hideki Tokaibayashi BRD	Director/Board Member	41	01/03/2021
Hideo Nakashima BRD	Director/Board Member	62	01/03/2021
Kiyoto Kiuchi BRD	Director/Board Member	35	29/03/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TELLA, INC.	-50.00%	-80.00%	-	-	342K
LONZA GROUP AG	-1.29%	-2.54%	-0.35%	+4.30%	49.7B
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+376.72%	+599.59%	38.09B
BEONE MEDICINES AG	-1.70%	+4.46%	+7.46%	+57.67%	35.29B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+26.35%	-6.83%	35.13B
CELLTRION, INC.	+0.06%	+1.56%	+4.41%	+27.42%	27.22B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.14B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+68.48%	+117.39%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+2.15%	+16.24%	+19.12%	13.89B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+15.74%	-30.62%	13.02B
Average	-4.98%	-0.57%	+64.38%	+98.50%	27.09B
Weighted average by Cap.	-0.15%	-0.64%	+75.20%	+119.74%

tella, Inc. Stock

Stocks

2191

JP3545900007

Biotechnology & Medical Research

Latest news : tella, Inc.

News in other languages: tella, Inc.

Quotes and Performance

Managers and Directors: tella, Inc.

Other Biotechnology & Medical Research

Company Profile